乳腺癌血液中微生物群和肠道微生物代谢产物的综合分析
Integrated analysis of microbiota and gut microbial metabolites in blood for breast cancer
影响因子:4.60000
分区:生物学2区 / 微生物学2区
发表日期:2024 Nov 19
作者:
Yu Peng, Jiale Gu, Fubin Liu, Peng Wang, Xixuan Wang, Changyu Si, Jianxiao Gong, Huijun Zhou, Ailing Qin, Fangfang Song
摘要
肠道微生物群和相关的代谢产物与乳腺癌发生有关。证据表明，血液菌群主要起源于肠道，可能是乳腺癌的生物标志物。我们的目的是表征血液中的微生物群微生物代谢物串扰，并为乳腺癌开发复合诊断面板。我们对107例乳腺癌病例和107个年龄对照的血液样本进行了16S rRNA基因测序和代谢组学分析。我们发现，与对照组相比，乳腺癌的血液微生物群的α多样性降低了。这两组之间的血液中，微生物群和肠道微生物代谢物的谱图显着不同，患者有9种细菌属，四个肠道微生物代谢产物增加，而39个细菌属和两个肠道微生物代谢产物在对照组中增加。一些与乳腺癌相关的肠道微生物代谢产物与差异血液微生物群有关，并进一步开发了一个复合的微生物群 - 代谢物诊断面板，乳腺癌的曲线下方的面积为0.963。这项研究强调了微生物群和肠道微生物代谢物在血液中的关键作用及其在乳腺癌发生中的相互作用，以及复合诊断面板作为乳腺癌的非侵入性生物标志物的潜力。物种综合分析表明，综合分析表明，微生物群和肠毒性症患者的乳腺癌癌症患者的乳腺癌癌和癌症患者的乳腺癌癌症患者的乳腺癌癌症患者的乳腺癌为癌症患者的变化改变。菌群与肠道微生物代谢产物之间的广泛相关性有助于理解乳腺癌的发病机理。血液中复合微生物群微生物代谢物面板的良好性能表明，一种无创的乳腺癌检测方法以及一种新的策略，以更好地诊断和预防乳腺癌。
Abstract
Gut microbiota and associated metabolites have been linked to breast carcinogenesis. Evidences demonstrate blood microbiota primarily originates from the gut and may act as a biomarker for breast cancer. We aimed to characterize the microbiota-gut microbial metabolites cross-talk in blood and develop a composite diagnostic panel for breast cancer. We performed 16S rRNA gene sequencing and metabolomics profiling on blood samples from 107 breast cancer cases and 107 age-paired controls. We found that the alpha diversity of the blood microbiota was decreased in breast cancer compared to controls. There were significantly different profiles of microbiota and gut microbial metabolites in blood between these two groups, with nine bacterial genera and four gut microbial metabolites increased in patients, while thirty-nine bacterial genera and two gut microbial metabolites increased in controls. Some breast cancer-associated gut microbial metabolites were linked to differential blood microbiota, and a composite microbiota-metabolite diagnostic panel was further developed with an area under the curve of 0.963 for breast cancer. This study underscored the pivotal role of microbiota and gut microbial metabolites in blood and their interactions for breast carcinogenesis, as well as the potential of a composite diagnostic panel as a non-invasive biomarker for breast cancer.IMPORTANCEOur integrated analysis demonstrated altered profiles of microbiota and gut microbial metabolites in blood for breast cancer patients. The extensive correlation between microbiota and gut microbial metabolites in blood assisted the understanding of the pathogenesis of breast cancer. The good performance of a composite microbiota-gut microbial metabolites panel in blood suggested a non-invasive approach for breast cancer detection and a novel strategy for better diagnosis and prevention of breast cancer in the future.